Aiolos Bio: GSK concludes Aiolos Bio acquisition for $1.4bn
GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, expanding its respiratory portfolio.
Read full article »
Aiolos Bio is a Massachusetts-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for respiratory and inflammatory diseases.
Read more